Stock ATHE ALTERITY THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Alterity Therapeutics Limited Nasdaq

Equities

ATHE

US02155X2053

Market Closed - Nasdaq
Other stock markets
 21:30:00 24/05/2024 BST 		5-day change 1st Jan Change
2 USD +3.11% Intraday chart for Alterity Therapeutics Limited 0.00% -19.68%
05-08 Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review CI
05-08 Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
CI
Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November
MT
Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases
CI
ADRs End Lower, Purple Biotech Ltd. Declines 29%
DJ
ADRs End Higher, Lixiang Education Holding Co. Ltd. Climbs 69%
DJ
ADRs Close Lower; VIA Optronics AG Declines 30%
DJ
Top Midday Gainers
MT
Alterity Therapeutics Receives AU$3.9 Million R&D Tax Refund
MT
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023
CI
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 30, 2023
CI
Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
CI
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease
CI
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy
CI
Alterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System Atrophy
CI
Alterity Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023
CI
Alterity Therapeutics Says it Secured European Patent Covering Neurodegenerative Disease Drug Candidates
MT
Alterity Therapeutics Limited Grants New Composition of Matter Patent in Europe for Neurodegenerative Diseases Including Parkinson's and Alzheimer's
CI
Alterity Therapeutics Limited Announces an Independent Data Monitoring Committee Recommends the ATH434-201 Phase 2 Study
CI
Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder
CI
Alterity Therapeutics Enrolls First Patient in Australia in Ath434 Global Phase 2 Clinical Trial in Multiple System Atrophy
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATH Stock
  4. ATHE Stock
  5. News Alterity Therapeutics Limited
  6. Highlights